Lumiracoxib, a highly selective COX-2 inhibitor
Raban V Jeger1, Jeffrey D Greenberg, Krishnan Ramanathan
1New York University School of Medicine, Cardiovascular Clinical Research Center, VA, NY 10010, USA. raban.jeger@med.nyu.edu
Expert Review of Clinical Immunology
|May 19, 2010
Summary
Lumiracoxib, a selective cyclooxygenase-2 inhibitor, significantly reduces gastrointestinal ulcer complications compared to traditional NSAIDs. Cardiovascular safety was comparable, but caution is advised pending further cardiovascular risk population studies.
Area of Science:
- Pharmacology
- Gastroenterology
- Pain Management
Background:
- Lumiracoxib is a selective cyclooxygenase-2 (COX-2) inhibitor approved for pain relief.
- Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) carry risks of gastrointestinal complications.
- The safety profile of COX-2 inhibitors remains a subject of ongoing research.
Purpose of the Study:
- To evaluate the efficacy and gastrointestinal safety of lumiracoxib.
- To compare lumiracoxib's gastrointestinal and cardiovascular outcomes against naproxen and ibuprofen.
- To assess lumiracoxib's safety in a population without gastroprotection.
Main Methods:
- The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) was conducted.
- Lumiracoxib was compared to naproxen and ibuprofen.
- Gastrointestinal ulcer complication rates and cardiovascular morbidity/mortality were primary endpoints.
Main Results:
- Lumiracoxib demonstrated a 66% overall reduction in gastrointestinal ulcer complications.
- A 79% reduction in ulcer complications was observed in nonaspirin users without gastroprotection.
- No statistically significant difference in cardiovascular morbidity and mortality was found compared to nonselective NSAIDs.
Conclusions:
- Lumiracoxib offers significant gastrointestinal safety benefits over traditional NSAIDs.
- Current evidence suggests comparable cardiovascular safety, but further research is needed.
- Limited use in patients at high risk for gastrointestinal complications is recommended until broader cardiovascular data is available.
Related Concept Videos
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...